Globe Newswire
--ACTIVATE includes 2 Complete Responses, 4 Partial Responses and 10 patients with Stable Disease as of April 2022 data cut off-- --Etigilimab safe and well tolerated, no new safety signals-- --Prioritization initiatives extend cash runway to late 2024-- LONDON and REDWOOD CITY, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or “the Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced updated cl